Altération de l'ADN/réparation de l'ADN

<p>TAS-103 dihydrochloride (BMS-247615 dihydrochloride) is a novel anticancer agent targeting both topoisomerase (Topo) I and Topo II.</p>

<p>KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ.</p>

<p>Hypericin (Cyclosan) is a natural anthraquinone compound. Hypericin exhibits antimicrobial, antiviral, antitumor, and antidepressant effects. Cost-effective and quality-assured.</p>

<p>PIK-75, a DNA-PK and PI3K inhibitor, suppresses DNA-PK(IC50=2 nM), p110α(IC50=5.8 nM) and p110γ(IC50=76 nM).</p>

<p>RG108 (N-Phthalyl-L-tryptophan) is an DNA methyltransferase inhibitor(IC50=115 nM).</p>

<p>ETP-46464 is an effective and specific ATR inhibitor (IC50: 25 nM).</p>

Brincidofovir (HDP-CDV) is an orally active, lipophilic form of cidofovir.

<p>Neobavaisoflavone: DNA polymerase inhibitor, potential for treating bone loss, anti-inflammatory, reduces ROS, RNS, cytokines in macrophages.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mouse PARP2. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse PARP2. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mouse PARP2, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse PARP2 in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>CBHcy, a dual substrate analog, is a specific BHMT inhibitor that may induce cysteinemia.</p>

<p>Semustine, a DNA alkylating agent, is a cancer chemotherapy compound that is nephrotoxic in patients with malignant melanoma receiving adjuvant chemotherapy for</p>

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM, exhibits > 200-fold selectivity over other HDAC.

<p>MDL-800 is a SIRT6 modulator with antitumor activity for the study of hepatocellular carcinoma and non-small cell lung cancer.</p>

<p>IndiMitecan (LMP776) is an inhibitor of topoisomerase I (Top1) with anticancer activities [1].</p>

CHDI-390576 is an HDAC inhibitor that inhibits class IIa HDAC 4, HDAC 5, HDAC 7, and HDAC 9, and can be used in cancer research.

<p>Exatecan (DX-8951f) is a DNA topoisomerase I (TOP1) inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL).Exatecan has antitumor activity and may be used in</p>

<p>Mirin is a Mre11-Rad50-Nbs1 (MRN) complex inhibitor and also inhibits Mre11-associated exonuclease activity.Mirin induces cell cycle arrest in G1 phase.</p>

<p>Cyclophosphamide-d4 is a deuterated compound of Cyclophosphamide. Cyclophosphamide has a CAS number of 50-18-0. Cyclophosphamide is an alkylating agent used in the treatment of several forms of cancer including leukemias, lymphomas and breast cancer.</p>

<p>PNU-159682 is a highly effective metabolite of the anthracycline nemorubicin.</p>

<p>ART0380 is a potent, antitumor, selective, orally available, ATP-competitive ATR kinase inhibitor for the study of ataxia telangiectasia mutated (ATM) cancer.</p>

BRD 4354 (ditrifluoroacetate) is a moderately potent inhibitor of HDAC5 and HDAC9 (IC50s: 0.85 and 1.88 μM).

<p>MY-1B is a nitrogen-substituted butenamide stereoprobe that blocks stereoselective enrichment of NSUN2, binding selectively to the C271 of NSUN2.</p>

<p>7-Methyladenine (NSC-7857) can be used as a marker of exposure to exogenous and carcinogenic methylating agents.</p>

DM-CHOC-PEN is a DNA alkylation agent that may be used to treat brain cancer.

DNA-PK-IN-5: potent DNA-PK inhibitor, reduces tumor repair, induces apoptosis, enhances radiotherapy, overcomes resistance.

<p>NK314, a benzo[c]phenanthridine, inhibits topoisomerase II causing DNA breaks within 1h, even without proteinase K digestion.</p>

<p>NHC-triphosphate is a weak alternative substrate for the viral polymerase and changes the mobility of the product in polyacrylamide electrophoresis gels.</p>

<p>3,6-Diamino-9(10H)-acridone is an inhibitor of topoisomerase [1].</p>

<p>DSO-5a, a potent and selective orally active BB3 agonist, is a DMAKO-00 derivative that enhances ppar-γ activity via BB3 and stimulates ERK1/2 phosphorylation.</p>

<p>Resminostat (4SC-201) is an orally bioavailable inhibitor of histone deacetylases (HDACs) with potential antineoplastic activity.</p>

<p>Pparδ agonist 7 is a potent agonist of Pparδ.</p>

<p>LT175 is a dual PPARα/γ partial agonist, insulin sensitizer, orally active, with lower adipogeny (EC50: hPPARα 0.22μm, mPPARα 0.26μm, hPPARγ 0.48μm).</p>

<p>Topoisomerase I inhibitor 6 traps DNA-Top1 complex, shows low non-cancer cell cytotoxicity, and has research value.</p>

<p>ITF3756 is a selective HDAC6 inhibitor.</p>

<p>Sabarubicin: a doxorubicin analogue with potent antitumor effects; superior in DNA fragmentation and topoisomerase II poisoning.</p>

<p>PR-104: hypoxia-activated DNA cross-linker, pre-prodrug for nitrogen mustard, converts to PR-104A in tumors.</p>

<p>Cas9-IN-2, an apo-Cas9 binder, inhibits Cas9 (IC50=246 μM), blocking Cas9:gRNA formation, regulating Cas9 function.</p>

<p>17(S)-HDHA: A DHA derivative in human blood/cells and mouse brain; leads to 17(S)-resolvins; inhibits IL-1β and leukocyte trafficking.</p>

<p>Dihydro-5-azacytidine acetate (DHAC), a nucleoside analog, becomes integrated into DNA, thereby inhibiting DNA methylation, and exhibits antitumor activity [1</p>

CP 67015 has an inhibitory effect on the function of topoisomerase, and is a direct mutagen in mammalian cells, which has effects on gene and chromosome levels.

<p>TZD18, a novel PPAR alpha/gamma dual agonist, inhibits cell growth and induces apoptosis in human glioblastoma T98G cells.</p>

<p>Compound 22 is a potent topoisomerase II inhibitor (IC50=0.52μM), with strong anti-proliferative effects, arresting cells at G2/M.</p>

<p>Topoisomerase IIα-IN-2 (compound 5) is a DNA-binding ligands and a potent inhibitor of the topoisomerase TopoIIα.</p>

<p>DNMT3A-IN-1 is a potent, selective DNMT3A inhibitor with KI 9.16-18.85 μM (AdoMet) and 11.37-23.34 μM (poly dI-dC).</p>

<p>NCI172112 is is used to develop antitumor agents effective against CNS tumors.</p>

<p>DB-959, a PPAR agonist, is used potentially for the treatment of Alzheimer's disease.</p>

<p>LY-510929: PPAR agonist for hyperlipidemia, metabolic issues, type 2 diabetes.</p>

<p>SKLB-197 targets ATR, inhibiting it at 0.013 μM, and is inactive on 402 other kinases, showing potent antitumor effects on ATM-deficient tumors.</p>

PPARγ agonist 3, also known as Compound 18a, is a potent and selective agonist of PPARγ.

<p>LMP744 is a DNA intercalator and Topoisomerase I (Top1) inhibitor with antitumor activity.</p>